Critical Contrast: Proteon Therapeutics (PRTO) & Its Peers
Proteon Therapeutics (NASDAQ: PRTO) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Proteon Therapeutics to related businesses based on the strength of its valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and earnings.
Risk & Volatility
Proteon Therapeutics has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500. Comparatively, Proteon Therapeutics’ competitors have a beta of 0.61, suggesting that their average share price is 39% less volatile than the S&P 500.
This is a summary of current ratings for Proteon Therapeutics and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Proteon Therapeutics Competitors||866||3223||11693||232||2.71|
Proteon Therapeutics currently has a consensus target price of $3.43, indicating a potential upside of 85.59%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 47.29%. Given Proteon Therapeutics’ higher possible upside, equities analysts plainly believe Proteon Therapeutics is more favorable than its competitors.
Earnings & Valuation
This table compares Proteon Therapeutics and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Proteon Therapeutics||$2.95 million||-$28.52 million||-0.83|
|Proteon Therapeutics Competitors||$284.49 million||$33.78 million||81.47|
Proteon Therapeutics’ competitors have higher revenue and earnings than Proteon Therapeutics. Proteon Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
50.1% of Proteon Therapeutics shares are held by institutional investors. Comparatively, 50.0% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 36.3% of Proteon Therapeutics shares are held by insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This table compares Proteon Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Proteon Therapeutics Competitors||-5,309.53%||-218.50%||-39.43%|
About Proteon Therapeutics
Proteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of vonapanitase in patients undergoing creation of an arteriovenous fistula (AVF). The Company initiated the first of two Phase III trials, PATENCY-1, for vonapanitase in radiocephalic AVFs. Its vonapanitase product candidate is a recombinant human elastase under development as a treatment to prevent AVF and arteriovenous graft (AVG) patency loss.
Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.